Market closed · Next open: Monday 9:30 AM ET
Last update: Aug 28, 2026, 6:10 PM ET
Johnson & Johnson
$268.04 0.85% today
Market Closed

Why Johnson & Johnson (JNJ) stock moved

Updated Aug 30, 2026

Johnson & Johnson (JNJ) shares rose 0.9% to $268.04 as of August 30, 2026, a slight gain from the prior close of $265.77. BestStocks flagged the session as a material change for JNJ. The move is tied to company news. Below, we break down what changed for JNJ, why it matters for investors, how the stock reacted, and the catalysts on the calendar.

What happened

Company News

Warren Buffett recommends JNJ as a defensive stock amid market gambling concerns. Buffett's endorsement signals institutional confidence in JNJ's recession-resistant dividends and stability.

This summary describes the catalyst and move as first detected on Aug 28, 2026, 6:09 PM EDT; the stock has continued trading since, so the current price and percentage move (shown above) may be larger or smaller than the figures here.
NewsCompany-Specific MoveWeak confidence
Rel. volume
0.7×
Below Avg
Vs peers
Top 1 of 7 peers
Outperforming
Market cap
$645.9B
New York Stock Exchange
Analyst target
$282
+5.2% vs price
Price chart
Jul 30 – Aug 28
NNNNNNNNNFV$254$264$274Jul 30Aug 6Aug 14Aug 21Aug 28
E earnings
F filing
A analyst
V/N other
click a marker to highlight
Change events — click to jump to details

What it means for Johnson & Johnson investors

For Johnson & Johnson investors, the recent signals are mixed, leaving the near-term picture neutral / mixed. On the constructive side: Positive 0.9% session move; Positive price momentum. Weighing against that: JNJ fell 2.57% to $251.87 intraday despite posting first-quarter earnings that beat forecasts and raising full-year guidance; New SEC filing — review for material disclosures. Because the move outpaced peers, it looks driven by JNJ-specific developments rather than a broad sector rotation. Wall Street's consensus price target sits at $282.08, implying +5.2% upside from $268.04. BestStocks rates the overall signal quality weak (38/100). With earnings roughly 44 days out, the next report is the most likely near-term test of the move.

JNJ price reaction

JNJ last traded at $268.04, up $2.27 (+0.85%) from the previous close of $265.77. The session traded on 0.7× average volume (below avg), so participation was unremarkable. Its healthcare peer group moved a median -0.5% over the same stretch, leaving JNJ ahead of the group by 1.4 points. Over the past month the stock has ranged between $254.41 and $273.41, and it currently sits about 72% of the way up that band.

Bullish and bearish analyst opinions on Johnson & Johnson (JNJ)

The consensus analyst price target on Johnson & Johnson (JNJ) is $282.08, 5.2% above the recent $268.04. Over the past 90 days analysts logged 0 upgrades, 13 maintains, and 0 downgrades. Here is how the bullish and bearish cases on JNJ line up.

The bullish case

  • Wall Street's consensus price target of $282.08 implies +5.2% upside from $268.04.
  • The Street's most bullish target is $305.00 (+13.8%).
  • Positive 0.9% session move.
  • Positive price momentum.

The bearish case

  • The most bearish analyst target is $255.00 (-4.9%).
  • JNJ fell 2.57% to $251.87 intraday despite posting first-quarter earnings that beat forecasts and raising full-year guidance.
Bull vs bear balanceNeutral / Mixed
BearishNeutralBullish

Weighing both sides, BestStocks' composite read of recent signals is roughly balanced, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.

Analyst price targets and ratings are FMP consensus figures as of Aug 30, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.

Analyst expectations
Consensus target: $282+5.2%
= 13 maintains
Guggenheim maintained Buy · 2026-08-06
SEC filings watch
8-K2026-08-04
Material event — review for impact
high
8-K2026-07-29
Material event — review for impact
high
8-K2026-07-28
Material event — review for impact
high
10-Q2026-07-23
Quarterly financial results
medium
Peer context
JNJ+0.9%
LLY-0.3%
UNH-0.5%
PFE-0.2%
ABBV-1.0%
MRK-0.9%

Previous notable changes for JNJ

News2026-08-25+0.0%
J&J's Imaavy receives FDA approval as first-ever treatment for warm autoimmune hemolytic anemia.
News2026-08-24+1.0%
Johnson & Johnson reported record-breaking Q2 2026 results as earnings season winds down.
News2026-08-21+1.1%
JNJ's MONARCH QUEST 3 robotic bronchoscopy system gains FDA 510(k) clearance with AI-powered enhancements.
News2026-08-20-2.2%
Empire Life Investments sold 7,004 JNJ shares, reducing its stake by 4.6% in Q2.
Upcoming catalysts & outlook
Next earnings
2026-10-13 (est.)
in 44 days
10-Q Filing (est.)
2026-10-22
Medium impact
Thesis shift
Neutral / Mixed
bearish signal
Risk level
Medium
from change events

Frequently asked questions about JNJ

Why did Johnson & Johnson (JNJ) stock move?

JNJ rose 0.9% to $268.04. The move coincided with the context summarized above, which BestStocks classifies as a company-specific move, though no single company-specific catalyst was independently confirmed.

How much did JNJ stock rise?

JNJ gained 0.85% ($2.27) versus the prior close of $265.77, last trading at $268.04 on 0.7× average volume.

When is Johnson & Johnson's next earnings date?

JNJ's next earnings report is estimated for 2026-10-13 — about 44 days away.

What is the analyst price target for JNJ?

The consensus analyst price target for JNJ is $282.08, about 5.2% above the current $268.04. Over the past 90 days, analysts recorded 0 upgrades, 13 maintains, and 0 downgrades.

Is the JNJ move company-specific or sector-wide?

BestStocks classifies it as a company-specific move: the peer group moved a median -0.5% against JNJ's +0.9%. JNJ ranks top 1 of 7 peers.

How BestStocks tracks JNJ

This page is generated automatically by BestStocks' change-detection system after company news was detected and verified against independent data sources. It draws on 20 tracked change events for JNJ, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of August 30, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.

Data sources
FMP real-time & historical price dataSEC EDGAR filingsAnalyst ratings & price targets (FMP)Earnings calendar (FMP)
Educational research tool — not personalized investment advice. Data may be delayed.